Relationship between early administration of abciximab and TIMI flow in STEMI patients undergoing primary angioplasty: findings from a large regional STEMI network
Conclusion: Our results suggest that the use of abciximab, free from pharmacokinetic limits of oral P2Y12 inhibitors, should be considered in STEMI patients with early presentation before primary PCI.
Source: Journal of Cardiovascular Medicine - Category: Cardiology Tags: Research articles: Coronary artery disease Source Type: research
More News: Abciximab | Angioplasty | Cardiology | Cardiovascular | Coronary Angioplasty | Emergency Medicine | Heart | Heart Attack | Percutaneous Coronary Intervention | Statistics | Study